Superworth

Citius Pharmaceuticals EPS CTXR

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$2.13
Latest quarter, Q3 FY26
−$0.34
Fiscal year 2025
−$3.83

Citius Pharmaceuticals' earnings per share was −$2.13 over the twelve months to Jun 30, 2026.

In its latest quarter, Q3 FY26, it was −$0.34.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$3.83n/a
FY2024−$5.95n/a
FY2023−$0.22n/a
FY2022−$0.22n/a
FY2021−$0.27n/a
FY2020−$0.47n/a
FY2019−$0.78n/a
FY2018−$1.22n/a
FY2017−$1.91n/a
FY2016−$2.18n/a
FY2015−$1.50n/a
FY2014−$0.60n/a
FY2013$0.00n/a
FY2012$0.00n/a
FY2011$0.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.34n/a−$2.13
Q2 FY26−$0.95n/a−$2.59
Q1 FY26−$0.38n/a−$2.91
Q4 FY25−$0.46n/a−$3.83
Q3 FY25−$0.80n/a−$4.96
Q2 FY25−$1.27n/a−$5.73
Q1 FY25−$1.30n/a−$5.80
Q4 FY24−$1.59n/a−$5.95
Q3 FY24−$1.57n/a−$4.43
Q2 FY24−$1.34n/a−$2.92
Q1 FY24−$1.45n/a−$1.65
Q4 FY23−$0.07n/a−$0.22

Against its peers

Companies in Drug Manufacturers - General nearest Citius Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
CTXRCitius Pharmaceuticals−$2.13
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Citius Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.